相关实验视频

Updated: Jun 5, 2025

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

系统性硬化症中的纤维化机制和新的潜在疗法

Raffaele Barile¹, Cinzia Rotondo¹, Valeria Rella¹

¹Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Luigi Pinto 1, 71121, Foggia, Italy.

Postgraduate medical journal

|December 10, 2024

概括

系统性硬化症涉及免疫激活和纤维化. 新兴疗法针对原,细胞因子和细胞表面分子,以创新治疗策略.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
纤维化研究纤维化研究

背景情况:

系统性硬化症 (SSc) 是一种罕见的自身免疫性疾病,其特征是免疫细胞激活,内皮功能障碍和渐进性纤维化.
病理性纤维化SSc的结果来自细胞外基质合成障碍,影响皮肤和内部器官.
关键的分子参与者包括TGFβ,VEGF,Galectin-3和Wnt/β-catenin通路.

研究的目的:

审查系统性硬化症的新兴治疗证据.
专注于针对关键分子通路和细胞组件的创新治疗策略.
为SSc.提供潜在的新药标和治疗方法的洞察力.

主要方法:

对系统性硬化症的当前和新兴治疗策略的文献综述.
针对原,细胞因子和细胞表面分子的药物的分析.
对生物制剂,JAK抑制剂,IL-6通路调节剂,单克隆抗体和低甲基化剂的检查.

主要成果:

目前对SSc的治疗方法多样化,并根据疾病的亚型和进展量身定制.
单克隆抗体和低甲基化剂在抑制纤维化方面表现有前途.
新兴药物向特定的分子通路和参与SSc病变的细胞相互作用.

结论:

系统性硬化症的治疗需要一个多方面的方法.
向原,细胞因子和细胞表面分子是创新的SSc疗法的一个有希望的途径.
对新型治疗策略的进一步研究对于改善SSc患者的治疗结果至关重要.

关键词:

免疫学免疫学免疫学病理学的病理学类风湿病学类风湿病学

更多相关视频

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

相关概念视频

Introduction to Fibroblasts

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...